We are live on ! Find out more
IHAM

Integral Health Asset Management Portfolio holdings

AUM $2.09B
1-Year Est. Return 112.84%
This Fund
S&P 500
This Quarter Est. Return
+7.36%
1 Year Est. Return
+112.84%
3 Year Est. Return
+485.32%
5 Year Est. Return
+783.01%
10 Year Est. Return
–
AUM
$496M
AUM Growth
+$20M
Cap. Flow
+$16.5M
Cap. Flow %
3.33%
Top 10 Hldgs %
30.96%
Holding
92
New
31
Increased
21
Reduced
18
Closed
21

Top Buys

Rank Stock Value
1
SYK icon
Stryker
SYK
+$13.3M
2
ELV icon
Elevance Health
ELV
+$12.4M
3
RVTY icon
Revvity
RVTY
+$11.2M
4
BIIB icon
Biogen
BIIB
+$11.1M
5
HUM icon
Humana
HUM
+$9.89M

Top Sells

Rank Stock Value
1
DGX icon
Quest Diagnostics
DGX
+$15.6M
2
CI icon
Cigna
CI
+$14.9M
3
UHS icon
Universal Health Services
UHS
+$14.1M
4
ISRG icon
Intuitive Surgical
ISRG
+$11.7M
5
MRNA icon
Moderna
MRNA
+$10.7M

Sector Composition

Rank Sector Weight
1 Healthcare 96.57%
2 Consumer Staples 0.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GH icon
26
Guardant Health
GH
$22.2B
$8.2M 1.65%
350,000
-125,000
-26% -$3.57M
BAX icon
27
Baxter International
BAX
$14.3B
$8.11M 1.63%
+200,000
New +$8.48M
RVNC
28
DELISTED
Revance Therapeutics, Inc.
RVNC
$8.05M 1.62%
250,000
+10,000
+4% +$312K
BSX icon
29
Boston Scientific
BSX
$74.2B
$7.6M 1.53%
+152,000
New +$7.16M
RVMD icon
30
Revolution Medicines
RVMD
$44.1B
$7.47M 1.51%
+345,000
New +$8.5M
ALGN icon
31
Align Technology
ALGN
$12.3B
$7.35M 1.48%
+22,000
New +$6.49M
REPL icon
32
Replimune Group
REPL
$1.15B
$6.98M 1.41%
395,000
+175,000
+80% +$4.16M
KRYS icon
33
Krystal Biotech
KRYS
$9.68B
$6.81M 1.37%
85,000
-30,000
-26% -$2.36M
RETA
34
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$6.46M 1.3%
71,000
-14,000
-16% -$822K
NVST icon
35
Envista
NVST
$4.58B
$6.21M 1.25%
152,000
+52,000
+52% +$1.98M
NARI
36
DELISTED
Inari Medical, Inc. Common Stock
NARI
$6.17M 1.24%
+100,000
New +$6M
HOLX
37
DELISTED
Hologic
HOLX
$6.05M 1.22%
+75,000
New +$6.04M
MRNA icon
38
Moderna
MRNA
$24.2B
$5.38M 1.08%
35,000
-65,000
-65% -$10.7M
LFST icon
39
Lifestance Health
LFST
$4.39B
$5.27M 1.06%
+709,000
New +$3.93M
ALKS icon
40
Alkermes
ALKS
$8.26B
$5.05M 1.02%
+179,000
New +$4.88M
AGIO icon
41
Agios Pharmaceuticals
AGIO
$1.95B
$4.89M 0.99%
+213,000
New +$5.66M
LH icon
42
Labcorp
LH
$26.1B
$4.59M 0.92%
+23,280
New +$4.79M
SUPN icon
43
Supernus Pharmaceuticals
SUPN
$2.73B
$4.53M 0.91%
125,000
+85,000
+213% +$3.27M
CRSP icon
44
CRISPR Therapeutics
CRSP
$5.23B
$4.52M 0.91%
+100,000
New +$4.86M
ARGX icon
45
argenx
ARGX
$54.1B
$4.47M 0.9%
12,000
+2,000
+20% +$740K
ACHC icon
46
Acadia Healthcare
ACHC
$2.9B
$4.41M 0.89%
+61,000
New +$4.75M
SGRY icon
47
Surgery Partners
SGRY
$1.96B
$4.21M 0.85%
+122,000
New +$3.96M
NTRA icon
48
Natera
NTRA
$45.1B
$4.16M 0.84%
75,000
-12,000
-14% -$576K
ALNY icon
49
Alnylam Pharmaceuticals
ALNY
$29.6B
$4.01M 0.81%
20,000
-15,000
-43% -$3.15M
IRTC icon
50
iRhythm Holdings
IRTC
$4.02B
$3.72M 0.75%
30,000
+10,000
+50% +$1.08M
1
2
3 4

Similar funds

CL
CSS LLC Chicago, Illinois $2.09B AUM 58.96% 1-Year Est. Return
ACM
Analog Century Management New York $2.09B AUM 186.85% 1-Year Est. Return
ACG
Aventail Capital Group New York $2.09B AUM 43.81% 1-Year Est. Return
NSUP
NLB Skladi upravljanje premozenja Ljubljana $2.09B AUM
TP
Third Point New York $2.08B AUM 27.04% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.08B AUM
TA
TruWealth Advisors Metairie, Louisiana $2.08B AUM 21.15% 1-Year Est. Return
AG
Avala Global New York $2.08B AUM 87.66% 1-Year Est. Return

Integral Health Asset Management's Q1 2023 Portfolio in Review

As of Q1 2023, Integral Health Asset Management held 92 positions worth $496M, up 4.2% from $476M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Integral Health Asset Management deployed $16.5M of net new capital in Q1 2023, opening 31 new positions and adding to 21 existing holdings. Its largest new stake was Stryker: 50,000 shares worth $14.3M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 93% a quarter earlier, followed by Consumer Staples.

On the sell side, the largest reduction was Moderna, an estimated $10.7M trimmed.

  • Integral Health Asset Management's largest Q1 2023 buy was Stryker: 50,000 shares worth $14.3M.
  • Integral Health Asset Management added most to Elevance Health in Q1 2023, an estimated $12.4M increase.
  • Integral Health Asset Management's biggest Q1 2023 reduction was Moderna, cutting an estimated $10.7M.
  • Integral Health Asset Management fully exited Quest Diagnostics in Q1 2023, selling an estimated $15.6M.
  • Integral Health Asset Management's ten largest holdings make up 31% of its $496M portfolio in Q1 2023.
  • Integral Health Asset Management opened 31 new positions and closed 21 in Q1 2023.
  • Integral Health Asset Management's portfolio value rose 4.2% quarter-over-quarter to $496M.

Based on Integral Health Asset Management's 13F filing for Q1 2023, filed 9 May 2023.